- Investing Ideas
- German Pharmaceuticals & Biotech Healthy potentially undervalued
German Pharmaceuticals & Biotech Healthy potentially undervalued
Results
6
Companies which are potentially undervalued and in an acceptable financial position.
6 companies
Merck KGaA
Market Cap: €51.1b
Operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific.
MRK
€117.15
7D
3.8%
1Y
-1.3%
SCHOTT Pharma KGaA
Market Cap: €2.2b
Develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide.
1SXP
€14.68
7D
7.0%
1Y
-35.3%
Bayer
Market Cap: €40.1b
Operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.
BAYN
€40.74
7D
0.6%
1Y
94.4%
Evotec
Market Cap: €985.6m
Operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.
EVT
€5.55
7D
18.6%
1Y
-4.7%
Dermapharm Holding
Market Cap: €2.4b
Manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China.
DMP
€45.50
7D
8.7%
1Y
22.3%
Formycon
Market Cap: €323.6m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
FYB
€18.56
7D
-1.5%
1Y
-20.5%